Back to News
Market Impact: 0.25
Iovance To Highlight Positive TIL Therapy Readout Today In Metastatic Lung Cancer; Stock Up
Source: Nasdaq
Healthcare & Biotech
Iovance Biotherapeutics said it will host a conference call and live webcast on October 29, 2026, at 8:30 a.m. ET, to discuss positive results from Phase 2 registrational cohorts of its tumor-infiltrating lymphocyte therapy. The available article text provides no efficacy figures or further details on the results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IOVA0.65
More News
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share
- Aspen Neuroscience prices IPO at $15 per share on Nasdaq